COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Real World Study of Biosimilar Trastuzumab in Her2 Positive Breast Cancer (LB1802)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03892655
Recruitment Status : Recruiting
First Posted : March 27, 2019
Last Update Posted : April 8, 2020
Information provided by (Responsible Party):
Libbs Farmacêutica LTDA

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : March 2021
Estimated Study Completion Date : March 2024